Project Information
Grant agreement ID: 101080823
Status: Ongoing project
Overall budget: € 6,998,037.50
Funding: European Union’s Horizon Europe Research and Innovation programme
| Start date
July 2023 |
End date
June 2028 |
Coordinated by: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE – France
8
European partners
2
Associations involved
more than
8,5
millions of T1D patients worldwide
7
Work Packages
5
Years project
Humanized T1D models for human antigen-specific Tregs assessment
Start: July 2023
End: June 2027
WP leader
Objectives
To demonstrate the effectiveness of the selected TCR and to select the most effective TCR for clinical application using mouse models. Later on, an humanized mouse model will be generated to test the effect of TRC-engineered human Tregs.
Treg supporting strategies in vivo
Start: February 2025
End: December 2027
WP leader & Co Leader
Objectives
To improve TCR-engineered Tregs transfer in animals thanks to supported techniques development. Two strategies will be tested separately in order to select the most effective.
GMP-compliant production of antigen-receptor-engineered stable human Treg
Start: July 2023
End: June 2028
WP leader & Co Leader
Objectives
To obtain a validated, clinical-grade process to use TCR-engineered Tregs in a phase 1 clinical trial for patients with T1D. The primary goal is to gain access to a Good Manufacturing Practice (GMP) compliant process to produce TCR-engineered human Tregs.
Regulatory and Ethical aspects
Start: July 2023
End: June 2028
WP leader
Objectives
To perform the project (including animal studies) in strict accordance with national and EU regulations. The project will feature 2 transversal WP: WP6 Communication, dissemination and exploitation of results and WP7 Coordination and project management.
Communication, dissemination and exploitation of results
Start: July 2023
End: June 2028
WP leader
Objectives
To implement a comprehensive communication and dissemination strategy. This will involve the creation of dissemination tools and the establishment of links with patients’ associations. The partners will also develop an appropriate exploitation plan to ensure the protection, application, and further use of the project results.
Coordination and project management
Start: July 2023
End: June 2028
WP leader & Co Leader
Objectives
To implement an effective management structure to make sure ARTiDe achieves its objectives and impacts.
Human autoreactive Tregs and TCRs in health and T1D
Start: March 2023
End: December 2027
WP leader
Objectives
To identify potential and promising TCR candidates of Tregs in type 1 diabetic patients. A database will be generated from these experiments which will be analyzed using a machine learning strategy to develop a rational approach for selecting TCRs. At the end of this WP, a small number of TCRs will be selected to be tested in the other WP.